Six years studying
how drugs reach patients.
I trained as a pharmacist at Universidad Complutense de Madrid — six years understanding the science behind drugs, how they are made, how they work and how they fail. That foundation never left me.
It became the lens through which I see every market access challenge, every health technology assessment and every negotiation with payers. Science credibility is not background — it is the edge.
Master of Pharmacy · UCM · 2019
Into the market —
strategy, pricing, access.
From sales at Servier to business development at Teva — managing unprofitable generics, recovering €0.5M in revenue, implementing BI tools. Learning the commercial logic that the lab never teaches.
Then four years in consulting and HTA strategy: 10+ value dossiers for pharma and MedTech clients, accelerating access timelines by 30%, and satisfaction scores above 9/10.
Teva · Servier · PORIB · 2019–2022
AstraZeneca —
€200M portfolio,
high-stakes table.
Three years managing Access, Pricing and HTA for Immunology at AstraZeneca Spain — a portfolio with gross revenue of approximately €200M. Ten high-impact negotiations in under 15 months delivering over €20M in upside.
Led advisory boards with KOLs and payers. Co-designed market access brand plans. Mentored a senior team member to full autonomy in four months. Member of the Global Pricing Working Group.
Award: Best P&R Strategy · AstraZeneca 2023. ISPOR Top 5% Finalist 2025.
AstraZeneca · Madrid · 2022–2025
Now — independent,
building in parallel.
Today I operate independently: advising pharma organizations on their most complex strategic decisions, partnering with selected investment opportunities, mentoring ambitious professionals and conducting a PhD in Health Policy at Instituto de Salud Carlos III.
The common thread across everything I do: better thinking leads to better decisions, and better decisions create better outcomes — in healthcare, in business and in life.
PhD · ISCIII · Consulting · Investing · 2025–